Effects of cannabidiol without delta-9-tetrahydrocannabinol on canine atopic dermatitis: A retrospective assessment of 8 cases.

Objective: We aimed to examine the effects of cannabidiol (CBD)-containing hemp oil without delta-9-tetrahydrocannabinol (THC) as a supplemental treatment for canine atopic dermatitis (CAD), as well as its adverse effects, and effects on concurrent drug use in dogs. Animal: In this retrospective case series, 8 dogs with CAD were diagnosed by veterinary dermatologists certified by the Japanese Society of Veterinary Dermatology. Procedure: The medical records of dogs supplemented with CBD-containing hemp oil were evaluated with respect to signalment, physical examination, plasma C-reactive protein concentrations, pharmacologic management, the CAD Extent and Severity Index (4th iteration), and the Pruritus Visual Analog Scale. Results: Overall, CBD, used as a supplement in combination with other drugs, was well-tolerated over a wide dose range and decreased the occurrence of pruritus in dogs with CAD when ingested twice a day. Conclusion: This study provides the first report of supplementation with CBD without THC that was effective in controlling pruritic behavior in dogs with CAD. Clinical relevance: Further controlled studies are required to investigate the dose range, efficacy, and safety.

Effets du cannabidiol sans delta-9-tétrahydrocannabinol sur la dermatite atopique canine : évaluation rétrospective de huit cas. Objectif: Nous avons cherché à examiner les effets de l'huile de chanvre contenant du cannabidiol (CBD) sans delta-9-tétrahydrocannabinol (THC) en tant que traitement complémentaire de la dermatite atopique canine (CAD), ainsi que ses effets indésirables et ses effets sur les médicaments concomitants utilisés chez le chien. Animal: Dans cette étude rétrospective de cas, huit chiens atteints de CAD ont été diagnostiqués par des dermatologues vétérinaires certifiés par la Société japonaise de dermatologie vétérinaire. Procédure: Les dossiers médicaux des chiens supplémentés avec de l'huile de chanvre contenant du CBD ont été évalués en ce qui concerne le signalement, l'examen physique, les concentrations plasmatiques de protéine C-réactive, la gestion pharmacologique, l'indice CAD Extent and Severity Index (4ème itération) et le Pruritus Visual Analog Scale. Résultats: Dans l'ensemble, le CBD, utilisé comme supplément en association avec d'autres médicaments, a été bien toléré sur une large gamme de doses et a diminué l'apparition de prurit chez les chiens atteints de CAD lorsqu'il est ingéré deux fois par jour. Conclusion: Cette étude fournit le premier rapport de supplémentation en CBD sans THC efficace pour contrôler le comportement prurigineux chez les chiens atteints de CAD. Pertinence clinique: D'autres études contrôlées sont nécessaires pour étudier la gamme de doses, l'efficacité et l'innocuité.(Traduit par Dr Serge Messier).

Results of food challenge in dogs with cutaneous adverse food reactions.

BACKGROUND: Elimination diet trials and food challenge tests remain the gold standard for diagnosing cutaneous adverse food reaction (CAFR) in dogs. However, food challenge tests are difficult to perform owing to a lack of definite information on expected clinical signs and the time frame within which they develop after challenge. OBJECTIVES: To report the results of the food challenge test carried out in client-owned dogs under observation. METHODS AND MATERIALS: A retrospective evaluation of the medical records of dogs presenting with pruritus was performed. Skin infections and/or parasites were treated before inclusion in the study. Dogs that underwent an elimination diet with clinical improvement and relapse with food challenge tests were included in this study. A pruritus Visual Analog scale score was recorded as an index of pruritus before and at the end of the elimination diet trial before challenge. The onset of time to relapse of clinical signs and the body sites affected after food challenge testing were recorded by the owners. RESULTS: We examined the medical records of 310 dogs with pruritus. Of these, 46 dogs with a diagnosis of CAFR were enrolled in this study. Significant clinical improvement was observed after the elimination diet trial (P < 0.0001). All dogs exhibited pruritus, and none exhibited anaphylaxis after food challenge testing. Among these dogs, 60.9% developed pruritus within 12 h of food challenge. Notably, 23.9% of the dogs developed pruritus within 3-6 h. The limbs exhibited the highest frequency of pruritus (56.5%), followed by the face (26.1%). CONCLUSIONS AND CLINICAL RELEVANCE: This study is the first to report details of the time to onset of clinical signs and body site affected after food challenge testing in dogs. These results will assist veterinarians and dog owners in the decision-making process regarding food challenge testing.

[Optimum Refocus Flip Angle of Non-contrast Magnetic Resonance Angiography Using ECG-gated 3D-TSE].

PURPOSE: In triggered acquisition noncontrast enhancement magnetic resonance angiography using ECG-gated with short-term inversion recovery (STIR-TRANCE), signal intensity and contrast fluctuate according to the value of refocus flip angle (RFA). We believe that we can visualize the pulmonary vascular excellently by optimized RFA which improves the signal intensity of pulmonary vascular and the contrast between pulmonary vascular and lung parenchyma. The purpose of this study is to optimize RFA in pulmonary vascular magnetic resonance angiography (MRA) imaging using STIR-TRANCE. METHOD: Pulmonary vascular MRA was performed in five normal volunteers. The department's ethics committee approved the study, and informed consent was obtained from all subjects. Before the STIR-TRANCE study, an ECG-gated single shot TSE (SS TSE) scan was performed to determine the timing of diastole. Later, the diastolic STIR-TRANCE imaging using both ECG and respiratory gating was performed with three different RFA (140 degree, 160 degree, and 180 degree). For physical evaluation, we used the signal to noise ratio (SNR) and contrast and for visual evaluation, so we used the Scheffe's method. RESULTS: SNR increases with increasing RFA. The contrast of 160 degree was significantly higher than the contrast of 180 degree. There was no significant difference in visual evaluation. CONCLUSION: From the perspective of specific absorption rate (SAR) reduction, we concluded that the optimal RFA for pulmonary vascular MRA in this study was 160 degree.

Oral faecal microbiota transplantation for the treatment of Clostridium difficile-associated diarrhoea in a dog: a case report.

BACKGROUND: Successful clinical outcomes of faecal microbiota transplantation (FMT) for recurrent Clostridium difficile infection have been reported in humans and a marmoset. However, it has been unclear whether oral FMT was effective for the treatment of C. difficile-associated diarrhoea in dogs. CASE PRESENTATION: An 8-month-old, intact male French bulldog was presented with a 4-month history of intermittent large bowel diarrhoea. Physical and clinical examinations did not identify any specific causes for diarrhoea. Real-time PCR analysis and immunochromatography detected C. difficile antigen and toxin A&B genes and proteins in a faecal sample. Based on these findings, diarrhoea in the dog was considered to be induced by C. difficile-associated colitis. The dog was treated with oral FMT, in which a faecal solution obtained from a healthy beagle was orally administered to the subject. Stool consistency and frequency and faecal blood and mucus became normal 2-3 days after oral FMT, and real-time PCR analysis and immunochromatography was negative for C. difficile antigen and toxin A&B genes and proteins. No adverse events were observed. CONCLUSION: The present case report demonstrated that oral FMT was an effective treatment for C. difficile-associated diarrhoea in a dog. The findings in this report provide a rationale to evaluate clinical efficacy of oral FMT for other gastrointestinal diseases in dogs.

Pilot evaluation of a single oral fecal microbiota transplantation for canine atopic dermatitis.

The gut microbiota has been suggested to be involved in the pathogenesis of canine atopic dermatitis (cAD). However, the gut microbiota has not been well characterized in dogs with atopic dermatitis (AD). In addition, the efficacy of fecal microbiota transplantation (FMT) in dogs with AD remains unclear. This research, therefore, aimed to characterize the gut microbiota of dogs with AD and conduct pilot evaluation of the efficacy of a single oral FMT on clinical signs and the gut microbiota of dogs with AD. For these purposes, we used 12 dogs with AD and 20 healthy dogs. The 16S rRNA analysis of the fecal microbiota revealed significant differences between 12 dogs with AD and 20 healthy dogs. Next, a single oral FMT was performed in 12 dogs with AD as a single-arm, open-label clinical trial for 56 days. A single oral FMT significantly decreased Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04 scores from day 0 (median score, 16.5) to day 56 (8) and Pruritus Visual Analog Scale (PVAS) scores from days 0 (median score, 3) to day 56 (1). Furthermore, a single oral FMT changed the composition of the fecal microbiota of dogs with AD at the phylum and genus levels. The number of common amplicon sequence variants in the fecal microbiota between donor dogs and dogs with AD was positively correlated with CADESI-04 and PVAS reduction ratios 56 days after FMT. Our findings suggest that the gut microbiota plays a pivotal role in the pathogenesis of cAD, and that oral FMT could be a new therapeutic approach targeting the gut microbiota in cAD.

Effects of a selective casein kinase 1δ and ε inhibitor on FcεRI expression and IgE-mediated immediate-type cutaneous reactions in dogs.

The molecular clock network in mast cells has been shown to be a factor responsible for circadian regulation of allergic inflammation. PF670462 is a selective inhibitor of casein kinase 1δ and ε (CK1δ/ε) that control the posttranslational modification of clock proteins. The aims of this study were to evaluate the effects of PF670462 on gene and protein expression of FcεRI, the high-affinity IgE receptor, in canine mast cells and on IgE-mediated immediate-type cutaneous reactions in dogs. PF670462 decreased mRNA expression of FcεRIα and ß, but not γ, and protein expression of FcεRI in a canine mast cell line. Furthermore, PF670462 suppressed IgE-mediated immediate-type cutaneous erythema in dogs. These findings indicate that CK1δ/ε function as regulators for FcεRI expression and IgE-mediated cutaneous reactions in dogs.

Prevalence of food-responsive enteropathy among dogs with chronic enteropathy in Japan.

There have been limited reports on the prevalence of adverse food reactions among dogs suffering from chronic enteropathy (CE) in Japan. We examined the prevalence and histological features of food-responsive enteropathy (FRE) in a total of 32 dogs with history of CE. Fourteen of 18 cases (56.2%) diagnosed as FRE had lymphocytic-plasmacytic enteritis or eosinophilic enteritis by histopathological examination. Characteristic histopathological changes indicating FRE were not identified in 18 cases, though 4 cases did not show any abnormalities. Results collected from this study provided important information that can help to change the way dogs with CE are treated in the future.

Lesional expression of thymus and activation-regulated chemokine in canine atopic dermatitis.

In this study, we investigated the mRNA expression of a chemokine, thymus and activation-regulated chemokine (TARC), and cytokines including IL-1beta, IL-4, IFN-gamma and TNF-alpha in skin samples obtained from both dogs with atopic dermatitis (AD) and healthy dogs. TARC mRNA was found to be selectively expressed in lesional skin of the dogs with AD, but not in non-lesional skin of the dogs with AD or the normal skin of the healthy dogs. The expression levels of IL-1beta, IFN-gamma and TNF-alpha in the lesional skin were also significantly higher than those in the non-lesional skin of the dogs with AD. However, IL-4 mRNA was not detected in any of the skin samples in this study. The present results suggest that TARC and inflammatory cytokines such as IL-1beta, IFN-gamma and TNF-alpha may play roles in the pathogenesis of canine AD as well as that of human AD.

Separate limbal-conjunctival autograft transplantation using the inferior conjunctiva for primary pterygium.

BACKGROUND: Inferior limbal-conjunctival autograft transplantation has been described as a safe and effective treatment for primary pterygium. However, despite its multiple advantages, routine performance of this technique is difficult because the inferior conjunctiva is often too small to provide enough autograft material. To resolve this issue, we modified a technique, inferior separate limbal-conjunctival autograft transplantation, and evaluated its efficacy and safety MATERIALS AND METHODS: A total of 50 eyes of 47 patients were retrospectively studied. Our surgery consisted of a thorough pterygium excision followed by 0.02% mitomycin C application. Next, we performed inferior conjunctival autografting, in which limbal and bulbar conjunctival autografts were independently harvested and secured to the denuded limbus and the most posterior conjunctival defect at the pterygium excision site to ensure stem-cell restoration and deep fornix reconstruction, respectively; the bare sclera between the two grafts was exposed. The outcome was assessed with a three-point grading scale at the patient's last visit. RESULTS: The success and recurrence rates were 96.0% (48 of 50) and 0%, respectively, assessed at follow-ups occurring at a mean of 19.2 ± 5.6 months after surgery. Only minimal complications were encountered. CONCLUSION: A combination of inferior separate limbal-conjunctival autograft transplantation with intraoperative 0.02% mitomycin C application is a safe and effective technique enabling the routine use of under-sized autografts harvested from the inferior conjunctiva after thorough pterygium excision.